to-BBB realizes €4M investment round

07-Feb-2011 - Netherlands
to-BBB Holding BV has realized a first close of its Series-B investment round at €4Million. The company welcomes the Dutch Healthcare Investors of Jonghoud International BV and the Boston Life Science fund of the Industrial Bank of Taiwan Management Corporation (IBTM). The existing investors Aescap Venture and Antea Participaties also contributed to the round, which will enable to-BBB to enter the clinic with its brain cancer lead product before the summer and to develop other potential CNS therapies that utilize the company’s proprietary G-Technology® for brain drug delivery.
With this new investment to-BBB will obtain important clinical validation for its G-Technology by performing a phase I/II study with its lead product 2B3-101. This product for multiple brain cancer types will initially be studied in patients with brain metastases of breast cancer. The study will start in Q2 2011 and is planned to treat 30 patients. Furthermore, the company will broaden the application of the G-Technology in several other CNS indications both internally and with partners. In the last year the company has signed 10 collaborations with pharma companies to explore to-BBB’s proprietary G-Technology for development of CNS therapies.
This Series-B round supplemented by additional non-dilutive (governmental) funding programs will support the company for two years to make these important value steps. Patrick Krol, Partner at Aescap Venture and Chairman of to-BBB concludes: “The financing round will enable to-BBB to prove the strength of the G-Technology in patients and allow the company to further increase its value in other CNS diseases such as Alzheimer’s Disease and MS.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances